GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pliant Therapeutics Inc (NAS:PLRX) » Definitions » Pretax Margin %

Pliant Therapeutics (Pliant Therapeutics) Pretax Margin % : % (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Pliant Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Pliant Therapeutics's Pre-Tax Income for the three months ended in Mar. 2024 was $-46.96 Mil. Pliant Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Pliant Therapeutics's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for Pliant Therapeutics's Pretax Margin % or its related term are showing as below:

PLRX' s Pretax Margin % Range Over the Past 10 Years
Min: -68847.98   Med: -1273.32   Max: -1.11
Current: -68847.98


PLRX's Pretax Margin % is ranked worse than
97.37% of 1027 companies
in the Biotechnology industry
Industry Median: -155.32 vs PLRX: -68847.98

Pliant Therapeutics Pretax Margin % Historical Data

The historical data trend for Pliant Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pliant Therapeutics Pretax Margin % Chart

Pliant Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial -1.11 -99.32 -1,284.51 -1,273.32 -10,211.14

Pliant Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,818.92 -16,609.68 - - -

Competitive Comparison of Pliant Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Pliant Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pliant Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pliant Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Pliant Therapeutics's Pretax Margin % falls into.



Pliant Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Pliant Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-161.336/1.58
=-10,211.14 %

Pliant Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-46.955/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pliant Therapeutics  (NAS:PLRX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Pliant Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Pliant Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pliant Therapeutics (Pliant Therapeutics) Business Description

Traded in Other Exchanges
Address
260 Littlefield Avenue, South San Francisco, CA, USA, 94080
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Executives
Hans Hull officer: Chief Business Officer C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Eric Lefebvre officer: Chief Medical Officer C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Keith Lamont Cummings officer: Chief Financial Officer C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Bernard Coulie director, officer: President and CEO C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Mike Ouimette officer: General Counsel C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Thomas A Mccourt director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Lily Cheung officer: Chief Human Resource Officer 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Katharine Knobil director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612
Third Rock Ventures Gp Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Kevin P Starr 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Smital Shah director C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129

Pliant Therapeutics (Pliant Therapeutics) Headlines

From GuruFocus

Pliant Therapeutics to Participate in Upcoming Investor Events

By sperokesalga sperokesalga 03-01-2023

Pliant Therapeutics to Participate in Upcoming Investor Events

By sperokesalga sperokesalga 05-10-2023

Pliant Therapeutics Announces Proposed Public Offering of Common Stock

By Stock market mentor Stock market mentor 01-23-2023